Methylphenidate Hydrochloride Extended Release NDC 10702-075

NDC codes

FDA NDC Directory

Product NDC (as listed)10702-075Labeler and product segments. Claims need a package NDC.

Product NDC at billing width10702-0075Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
10702-075-01	10702007501	100 TABLET in 1 BOTTLE (10702-075-01)Marketed from Jun 9, 2015
10702-075-06	10702007506	60 TABLET in 1 BOTTLE (10702-075-06)Marketed from Jun 9, 2015

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methylphenidate Hydrochloride Extended Release
Generic name (nonproprietary): methylphenidate hydrochloride extended release
Active ingredients: Methylphenidate hydrochloride — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: KVK-Tech, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207488
Marketing start: Jun 9, 2015
Listing expires: Dec 31, 2026
DEA schedule: CII
Other FDA classes: Central Nervous System Stimulation (Physiologic effect)
Identifiers: Product ID 10702-075_40950048-0e42-4661-e063-6394a90a2bb1SPL ID 40950048-0e42-4661-e063-6394a90a2bb1SPL set ID be8580bc-0eb2-4eb6-a4cc-4ebbeb33424dRxCUI 1091145, 1091225UNII 4B3SC438HI
Pharmacologic class: Central Nervous System Stimulant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N410702007501 followed by a unit qualifier and the quantity

Package 10702-0075-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 7, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of: • Attention Deficit Hyperactivity Disorders (ADHD) in pediatric patients 6 years and older and adults • Narcolepsy Limitations of Use: The use of Methylphenidate hydrochloride is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7), Use in Specific Populations (8.4)]. Methylphenidate hydrochloride extended-release tablet is a central nervous system (CNS) stimulant indicated for the treatment of Attenti…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207488

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207488
Product	Strength	Form · route	Labeler	Product NDC
Methylphenidate Hydrochloride Extended Release	Methylphenidate hydrochloride 20 mg/1	TabletOral	KVK-Tech, Inc.	10702-076